Notice of Results
Further to our announced intention to publish our audited 2019 full year results on 31 March 2020, the Board wishes to notify shareholders that this will now be postponed until Tuesday April 14th. This follows advice and additional guidance on financial reporting from the Financial Conduct Authority and the Financial Reporting Council in light of the ongoing coronavirus pandemic.
Notice of Results
he Directors of Proteome Sciences look forward to updating shareholders on the Company’s performance, and on the outlook for 2020, at the time of announcing the 2019 full year results which are scheduled for release on 31 March 2020.
Annual General Meeting
The Annual General Meeting of the Company will take place at the offices of Allenby Capital, 5 St Helen's Place, London EC3A 6AB, at 2.30pm on 29 April 2020. Formal notice of such will be posted to shareholders with the annual report in April.
Shareholding in Company and Director/PDMR Shareholding
The Company received notification yesterday from Vulpes Life Sciences Fund ("Vulpes") that on 28 February 2020 it purchased 256,424 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.00p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,203,158 Ordinary Shares, equivalent to approximately 22 per cent of the issued share capital of the Company.
Further Year End Trading Update Milestone Payment for TMT®/TMTpro™ Sales
The Company is pleased to provide a further trading update for the financial year ended 31 December 2019.
Year End Trading Update
The Company today provides a trading update for the financial year ended 31 December 2019.
Trading Update and Announcement of Board Changes
Proteome Sciences plc (AIM: PRM) is pleased to announce that its services platform has continued to strengthen through the third quarter, during which a record number of 43 quotes for new business were issued.
Interim results for the six months ended 30 June 2019
Commenting on these results, Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said:
“Performance during the first six months of 2019 was very encouraging, building on the momentum developed in the second half of 2018. Recognised revenues from our services platform were significantly ahead of the equivalent period in 2018 and, most importantly, we issued a record number of quotes for new business in the second quarter, a fundamental lead indicator of future customer engagement.
Launch of new services powered by TMTpro 16plex
Following the announcement of TMTpro 16plex isobaric mass tags during the American Society for Mass Spectrometry (ASMS) meeting in Atlanta in June, Proteome Sciences is launching upgrades to its core proteomic services (SysQuant®, TMTcalibrator™ and Plasma Super Depletion) with increased multiplexing.
New report on growing opportunities for TMT: “Tandem Mass Tag Usage Could Benefit From New Methods, Expanded Applications” available to premium subscribers of GenomeWeb
New report on growing opportunities for TMT: “Tandem Mass Tag Usage Could Benefit From New Methods, Expanded Applications” available to premium subscribers of GenomeWeb. Link here
Result of Annual General Meeting (AGM)
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 2.30 p.m. today, all resolutions were duly passed.
A copy of the presentation given by the CEO, Jeremy Haigh, at the AGM will be available on the Company’s website tomorrow. Link here to AGM slides